Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database

被引：0
|
作者：
Xiongwen Yang
Bo Yang
Dan Li
Wei Pan
Qin Tong
Lili Wang
Danjun Chen
Chengxiao Fu
机构：
[1] Hengyang Medical School,Department of Pharmacy, The First Affiliated Hospital
[2] University of South China,Institute of Pharmacy and Pharmacology, College of Basic Medical Science, Hengyang Medical School
[3] University of South China,Clinical Pharmacology Research Center, The First Affiliated Hospital
[4] Hengyang Medical School,Department of Oncology, The First Affiliated Hospital
[5] University of South China,undefined
[6] Hengyang Medical School,undefined
[7] University of South China,undefined
来源：
Clinical Drug Investigation | 2024年 / 44卷 / 3期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：199 / 207
页数：8
相关论文
共 50 条
  • [11] Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS)
    Jing Huang
    Yibei Zhao
    Yanni Cao
    Qingxia Zhang
    Dongzhi Ran
    Jinyan Li
    Ling Luo
    Feng Qiu
    Long Meng
    International Journal of Clinical Pharmacy, 2022, 44 : 993 - 1003
  • [12] Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS)
    Huang, Jing
    Zhao, Yibei
    Cao, Yanni
    Zhang, Qingxia
    Ran, Dongzhi
    Li, Jinyan
    Luo, Ling
    Qiu, Feng
    Meng, Long
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (04) : 993 - 1003
  • [13] Pharmacovigilance Analysis of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Events for Daprodustat
    Bell, Abraham
    Maddineni, Gautam
    Milutinovic, Stefan
    Bell, Isaac
    Oliveira, Meloney
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [14] Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
    Li, Yun
    Li, Hang
    Xiang, Zhongyuan
    HELIYON, 2024, 10 (06)
  • [15] Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
    Zhou, Jianxing
    Wei, Zipeng
    Xu, Baohua
    Liu, Maobai
    Xu, Ruichao
    Wu, Xuemei
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [16] Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)
    Cirmi, Santa
    El Abd, Asmae
    Letinier, Louis
    Navarra, Michele
    Salvo, Francesco
    CANCERS, 2020, 12 (04)
  • [17] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
  • [18] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [19] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [20] A pharmacovigilance study of adverse events associated with polymyxins based on the US Food and Drug Administration Adverse Event Reporting System (FAERS) database
    Wu, Tingxi
    Shi, Yanfeng
    Xu, Chang
    Zhu, Bin
    Li, Dandan
    Li, Zhe
    Zhao, Zhigang
    Zhang, Yang
    EXPERT OPINION ON DRUG SAFETY, 2025, 24 (01) : 69 - 77
12345